BIO4 Campus Belgrade: 1.000+ PhDs and 300+ Labs

BIO4 Campus Belgrade:
1.000+ PhDs and 300+ Labs

BIO4 Campus Belgrade:
1.000+ PhDs and 300+ Labs

Swiss Rockets AG brings its knowledge, technologies to Serbia


Minister of Science, Technological Development and Innovation Jelena Begovic and Executive Director of Swiss Rockets AG Vladimir Cmiljanovic signed a Memorandum of Understanding today in the government of Serbia, opening up new opportunities for the development of oncology and nuclear medicine.

After signing the Memorandum, Begovic explained that our people who live and work in Switzerland are the founders of an innovative company, i.e., a network of Swiss Rockets AG companies, with a large number of innovations in their portfolio, and that they decided to take this step and transfer their knowledge and technologies to Serbia.

This company will build a new innovation center for nuclear medicine within the BIO4 campus, Begovic said.

The Minister added that this company will also help the development of the startup ecosystem in the field of biotechnology in Serbia and that it has already started cooperation with our scientific and research institutes, such as INEP and the Institute of Chemistry, Technology and Metallurgy (IHTM).

Cmiljanovic pointed out that this company decided to enter into cooperation with our country for making the so-called theranostic innovation centre.

These are the most modern hospitals, where we will produce the latest molecules for personalised cancer medicine. We will work with the latest technologies for scanning patients with metastases and then based on these technologies we will be able to use those molecules to successfully treat patients with metastases, Cmiljanovic explained.

He added that this company from Switzerland transfers very important technologies to Serbia, as well as that these technologies will be further developed in our country.

Cmiljanovic pointed out that these projects are now very important for patients with tumors, primarily patients with prostate metastases, neuroendocrine tumors, glioblastomas and breast cancer.


Share This Story, Choose Your Platform!

Go to Top